Evidence map›Paper›PMID 40001420›Full record

ArticleAntibiotics (Basel, Switzerland)2025

Impact of Hydrophobic, Hydrophilic, and Mucus-Binding Motifs on the Therapeutic Potential of Ceftazidime Analogs for Pulmonary Administration.

Kyle D Apley, Stephanie N Johnson, Jian Qian, Indeewara Munasinghe, Jennifer R Klaus, Srilaxmi M Patel, Kathryn E Woods, Samalee Banerjee, Josephine R Chandler, Chamani Perera and 3 more

Abstract read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kyle D ApleyDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-7689-2215
Stephanie N JohnsonDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-4198-9113
Jian QianDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.
Indeewara MunasingheSynthetic Chemical Biology Core Laboratory, University of Kansas, Lawrence, KS 66045, USA.
Jennifer R KlausDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0001-9821-1487
Srilaxmi M PatelSynthetic Chemical Biology Core Laboratory, University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0001-7665-9731
Kathryn E WoodsDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA.
Samalee BanerjeeDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA.ORCID 0009-0006-0640-1181
Josephine R ChandlerDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA.
Chamani PereraSynthetic Chemical Biology Core Laboratory, University of Kansas, Lawrence, KS 66045, USA.
Nathalie BaumlinDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Matthias SalatheDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.ORCID 0000-0001-9092-4861
Cory J BerklandDepartment of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-7164-7886

Funding

Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI OROZCO, ROBIN C. · 2016 to 2025
$23.9M
Synthetic Chemical Biology CoreP30GM145499 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Susan M Lunte · 2022 to 2026
$6.9M
Mechanisms of mucociliary dysfunction in cystic fibrosis related diabetesR01HL157942 · NHLBI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI KIM, MICHAEL D, SALATHE, MATTHIAS A · 2021 to 2024
$2.7M
Quorum sensing evolution and function in mixed bacterial communitiesR35GM156409 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Josephine R Chandler · 2025 to 2026
$866k
Avance II 500 High Performance Digital NMR Spectrometer SystemS10RR024664 · NCRR · UNIVERSITY OF KANSAS LAWRENCE · PI VANDERVELDE, DAVID G · 2007 to 2007
$468k
Cystic Fibrosis Foundation BERKLA20A0NCRR NIH HHS S10 RR024664NHLBI NIH HHS R01 HL157942NIGMS NIH HHS P20 GM113117NIGMS NIH HHS P30 GM145499NIGMS NIH HHS R35 GM156409NIH HHS 1R01HL157943-01A1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antibacterial(s)drug designdrug transportepithelial permeabilitypulmonary drug delivery

Identifiers

PMID40001420
PMCPMC11852049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.